17 – Embracing Diversity and Inclusion in Clinical Trial Design

Jennifer Jones-McMeans, PhD

Divisional Vice President of Global Clinical Affairs, Abbott

Sep 14, 2022

Recruiting diverse participants to treat peripheral artery disease (PAD), a costly and dangerous medical condition with mortality rates three times that of breast cancer, is of significant importance. Discover how Abbott improves underserved communities’ access to clinical trials, better serving the patients most affected by vascular disease. PAD predominantly affects African Americans, who are twice as likely to have PAD as any other racial/ethnic group and four times as likely to require an amputation. Therefore, it is critical that both the doctors and patients who participate in this clinical trial reflect the underserved communities most in need of treatment.

Join this session to learn:

  • Why clinical trials must embrace diversity and inclusion.
  • Best practices for engaging diverse communities and encouraging participation in clinical trials.
  • The benefits of designing clinical trials representative of the entire population.

This site uses cookies

We take pride in providing you with relevant, useful content. May we use cookies to track what you read? We take your privacy very seriously. Please see our privacy policy for details and any questions.